Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Reck Martin; Schenker Michael; Lee Ki Hyeong; Provencio Mariano; Nishio Makoto; Lesniewski-Kmak Krzysztof; Sangha Randeep; Ahmed Samreen; Raimbourg Judith; Feeney Kynan; Corre Romain; Franke Fabio Andre; Richardet Eduardo; Penrod John R.; Yuan Yong; Nathan Faith E.; Bhagavatheeswaran Prabhu; DeRosa Michael; Taylor Fiona; Lawrance Rachael; Brahmer Julie

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

【24h】

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

机译：Nivolumab Plus inpilemimab与化疗作为高级非小细胞肺癌的一线治疗，具有高肿瘤突变负担：患者报告的结果由随机，开放标签，III期检查培育227试验结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: In the phase I I I CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; >= 10 mutations/megabase).

机译：背景：在III期检查227研究中，一线Nivolumab + IpiLimumab显着延长了无进展的生存（共初级终点）与晚期Nonesmall-Cell-Cell肺癌（NSCLC）和高肿瘤突变负担的患者进行化疗（ TMB;> = 10个突变/兆瓣）。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共11页
作者
Reck Martin; Schenker Michael; Lee Ki Hyeong; Provencio Mariano; Nishio Makoto; Lesniewski-Kmak Krzysztof; Sangha Randeep; Ahmed Samreen; Raimbourg Judith; Feeney Kynan; Corre Romain; Franke Fabio Andre; Richardet Eduardo; Penrod John R.; Yuan Yong; Nathan Faith E.; Bhagavatheeswaran Prabhu; DeRosa Michael; Taylor Fiona; Lawrance Rachael; Brahmer Julie;
展开▼
作者单位

German Ctr Lung Res DZL ARCN LungenClin Grosshansdorf Wohrendamm 80 D-22927 Grosshansdorf;

Cent Oncol Sf Nectarie 23A Caracal St Craiova 200347 Romania;

Chungbuk Natl Univ Hosp 776 1 Sunhwan Ro Cheongju 28644 Chungcheonbuk D South Korea;

Univ Autonoma Madrid Inst Invest Puerta Hierro Hosp Puerta Hierro de Majadahonda C Manuel de;

Japanese Fdn Canc Res Canc Inst Hosp Koto Ku 3-8-31 Ariake Tokyo 1358550 Japan;

Gdansk Med Univ Oddzial Onkol Radioterapii Szpital UI Powstania Styczniowego 1 PL-81519 Gdynia;

Cross Canc Inst 11560 Univ Ave Edmonton AB T6G 1Z2 Canada;

Univ Hosp Leicester NHS Trust Dept Infect Leicester LE1 5WW Leics England;

Inst Cancerol Ouest Ctr Rene Gauducheau Blvd Jacques Monad F-44805 Nantes France;

Notre Dame Univ 100 Murdoch Dr Perth WA 6150 Australia;

CHU Rennes 2 Rue Henri le Guilloux F-35033 Rennes France;

Hosp Caridade Ijui CACON Av David Jose Martins BR-98700000 Ijui RS Brazil;

IONC Univ Catolica Cordoba Parana 560 2 Piso RA-5000 Cordoba Argentina;

Bristol Myers Squibb Co 3401 Princeton Pike Lawrenceville NJ 08648 USA;

Bristol Myers Squibb Co 3401 Princeton Pike Lawrenceville NJ 08648 USA;

Bristol Myers Squibb Co 3401 Princeton Pike Lawrenceville NJ 08648 USA;

Bristol Myers Squibb Co 3401 Princeton Pike Lawrenceville NJ 08648 USA;

Adelphi Values 290 Congress St 7th Floor Boston MA 02210 USA;

Adelphi Values 290 Congress St 7th Floor Boston MA 02210 USA;

Adelphi Values Grimshaw Ln Bollington SK10 5JB Cheshire England;

Johns Hopkins Sidney Kimmel Comprehens Canc Ctr 1650 Orleans St CRB1-G94 Baltimore MD 21287 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Antineoplastic agents; Carcinoma; Ipilimumab; Lung neoplasms; Nivolumab; Non-small-cell lung cancer; Platinum-doublet chemotherapy; Quality of life; Surveys and questionnaires;

机译：抗肿瘤剂;癌;IPILIMIMAB;肺肿瘤;幼虫病;非小细胞肺癌;铂 - 双细胞化疗;生活质量;调查和问卷;

相似文献

外文文献
中文文献
专利

1. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial [J] . Reck Martin, Schenker Michael, Lee Ki Hyeong, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Nivolumab Plus inpilemimab与化疗作为高级非小细胞肺癌的一线治疗，具有高肿瘤突变负担：患者报告的结果由随机，开放标签，III期检查培育227试验结果
2. CheckMate-227 shows superior progression-free Survival for Nivolumab in Combination with Ipilimumab versus Chemotherapy in the First-line Treatment of Patients with non-small cell Lung Cancer during high Tumor Mutation Burden [J] . Oncology research and treatment. . 2018,第3期

机译：checkmate-227显示了Nivolumab与Ipilimumab与化疗组合在高肿瘤突变负担期间的患者的肝脏和化疗中的卓越的进展生存
3. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J] . Horn Leora, Spigel David R., Vokes Everett E., Journal of Clinical Oncology . 2017,第35期

机译：Nivolumab对先前治疗的非小细胞肺癌患者的多西紫杉醇：两年随机，开放标签，第III期试验的两年成果（Checkmate 017和Checkmate 057）
4. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
5. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label phase 1 multicohort study [O] . Matthew D Hellmann, Prof. Naiyer A Rizvi, Jonathan W Goldman, -1

机译：Nivolumab + ipilimumab作为晚期非小细胞肺癌的一线治疗药物（CheckMate 012）：开放标签1期多队列研究的结果
6. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study [O] . Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, 2017

机译：Nivolumab加Ipilemimab作为先进的非小细胞肺癌的一线治疗（Checkmate 012）：开放标签，阶段，多级研究的结果

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

摘要

著录项

相似文献

相关主题

期刊订阅